1. Emerging Multiple Sclerosis Therapies

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Emerging DMTs and Unmet Needs in MS

4. Overview of Selected DMTs in Development

5. Cladribine

6. Cladribine vs Placebo in RRMS CLARITY

7. Cladribine vs Placebo in RRMS Post-Hoc Analyses of CLARITY

8. Cladribine vs Placebo in RRMS CLARITY Extension

9. S1P Receptor Modulators

10. Siponimod vs Placebo in SPMS EXPAND

11. Ozanimod vs IFN β-1a IM in RRMS SUNBEAM

12. Ozanimod vs IFN β-1a IM in RRMS RADIANCE Part B

13. Ponesimod vs Teriflunomide in RRMS OPTIMUM

14. Ponesimod + DMF vs DMF in RRMS POINT

15. ALKS 8700

16. ALKS 8700 vs DMF in RRMS EVOLVE-MS-1 and EVOLVE-MS-2

17. Monoclonal Antibodies Targeting CD20

18. Ofatumumab vs Placebo in RRMS MIRROR Phase 2 Study

19. Ofatumumab vs Teriflunomide in RRMS ASCLEPIOS I and ASCLEPIOS II

20. Ublituximab in RRMS Phase 2 Study

21. Ublituximab vs Teriflunomide in RRMS ULTIMATE I and ULTIMATE II

22. Opicinumab Anti-LINGO-1

23. Opicinumab vs Placebo in Optic Neuritis RENEW Phase 2 Study

24. Opicinumab + IFN β-1a IM vs IFN β-1a IM in RRMS or SPMS: SYNERGY Phase 2 Study

25. Temelimab (GNbAC1) Anti-MSRV-Env

26. Temelimab vs Placebo in RRMS: CHANGE-MS Phase 2 Study

27. Ibudilast

28. Ibudilast vs Placebo in SPMS and PPMS SPRINT-MS

29. Conclusions

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)